Trexquant Investment LP Purchases 195,841 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Trexquant Investment LP grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 297.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 261,749 shares of the company’s stock after purchasing an additional 195,841 shares during the period. Trexquant Investment LP’s holdings in Cellebrite DI were worth $2,267,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD bought a new stake in shares of Cellebrite DI in the 4th quarter valued at approximately $1,774,000. Voss Capital LLC boosted its holdings in shares of Cellebrite DI by 207.7% in the 4th quarter. Voss Capital LLC now owns 1,835,000 shares of the company’s stock worth $15,891,000 after acquiring an additional 1,238,580 shares in the last quarter. Brasada Capital Management LP boosted its holdings in shares of Cellebrite DI by 125.1% in the 3rd quarter. Brasada Capital Management LP now owns 375,332 shares of the company’s stock worth $2,762,000 after acquiring an additional 208,566 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Cellebrite DI by 30.7% in the 3rd quarter. Swiss National Bank now owns 107,800 shares of the company’s stock worth $825,000 after acquiring an additional 25,300 shares in the last quarter. Finally, IGP Investments G.P.L.P LP acquired a new position in shares of Cellebrite DI in the 4th quarter worth approximately $182,619,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Down 6.6 %

NASDAQ:CLBT opened at $11.10 on Friday. The stock’s fifty day moving average price is $11.11 and its two-hundred day moving average price is $9.91. Cellebrite DI Ltd. has a 52-week low of $5.45 and a 52-week high of $12.50.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $89.60 million for the quarter, compared to the consensus estimate of $85.34 million. Cellebrite DI had a positive return on equity of 220.14% and a negative net margin of 32.57%. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.03 EPS. Analysts forecast that Cellebrite DI Ltd. will post 0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLBT has been the topic of several recent analyst reports. Craig Hallum boosted their target price on Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Bank of America boosted their target price on Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Lake Street Capital started coverage on Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 target price on the stock. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday. Finally, William Blair raised Cellebrite DI from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $13.17.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.